PMID- 8601223
OWN - NLM
STAT- MEDLINE
DCOM- 19960503
LR  - 20191024
IS  - 1077-9450 (Print)
IS  - 1077-9450 (Linking)
VI  - 11
IP  - 4
DP  - 1996 Apr 1
TI  - Active HHV-6 infection in the lymph nodes of HIV-infected patients: in vitro 
      evidence that HHV-6 can break HIV latency.
PG  - 370-8
AB  - Studies published previously by this laboratory have demonstrated that patients 
      with AIDS have widely disseminated, active infections with HHV-6 at the time of 
      their death. However, it remains unclear when in the course of the human 
      immunodeficiency virus (HIV) infection the active HHV-6 infection first appears. 
      To address this question, lymph node biopsies from 10 HIV-infected patients were 
      analyzed for active human herpesvirus 6 (HHV-6) infections by immunohistochemical 
      staining. Eight of the biopsies carried the histologic diagnosis of follicular 
      hyperplasia; the other two were characterized as having follicular involution 
      with histiocytosis and reactive lymphadenitis. In total, 10 of 10 (100%) of the 
      lymph nodes studied contained cells productively infected with HHV-6; in 
      contrast, three lymph nodes with follicular hyperplasia and four normal lymph 
      nodes from patients not infected with HIV were negative for HHV-6 infection. Of 
      special note, the absolute CD4+ lymphocyte counts of 75% (6/8) of the 
      HIV-infected individuals included in these studies were > 200/mm3 at the time of 
      their lymph node biopsy. The A variant of HHV-6 was found to be the predominant 
      form of the virus present in the lymph node biopsies from all of these 
      HIV-infected patients, and in vitro studies demonstrated that exposure of 
      monocytic cells carrying latent HIV to HHV-6A resulted in massive upregulation of 
      HIV replication from latency. Thus, active HHV-6 infections appear relatively 
      early in the course of HIV disease, and in vitro studies suggest that the A 
      variant of HHV-6 is capable of breaking HIV latency, with the potential for 
      helping to catalyze the progression of HIV infections to AIDS.
FAU - Knox, K K
AU  - Knox KK
AD  - Department of Pathology, Medical College of Wisconsin, Milwaukee, USA.
FAU - Carrigan, D R
AU  - Carrigan DR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Acquir Immune Defic Syndr Hum Retrovirol
JT  - Journal of acquired immune deficiency syndromes and human retrovirology : 
      official publication of the International Retrovirology Association
JID - 9501482
RN  - 0 (HIV Core Protein p24)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - AIDS-Related Opportunistic Infections/*virology
MH  - CD4 Lymphocyte Count
MH  - HIV/*physiology
MH  - HIV Core Protein p24/analysis
MH  - HIV Infections/virology
MH  - Herpesviridae Infections/*virology
MH  - Herpesvirus 6, Human/*isolation & purification/physiology
MH  - Humans
MH  - Hyperplasia
MH  - Lymph Nodes/pathology/*virology
MH  - Monocytes/virology
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor-alpha/analysis
MH  - *Virus Activation
MH  - Virus Latency
EDAT- 1996/04/01 00:00
MHDA- 1996/04/01 00:01
CRDT- 1996/04/01 00:00
PHST- 1996/04/01 00:00 [pubmed]
PHST- 1996/04/01 00:01 [medline]
PHST- 1996/04/01 00:00 [entrez]
AID - 10.1097/00042560-199604010-00007 [doi]
PST - ppublish
SO  - J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Apr 1;11(4):370-8. doi: 
      10.1097/00042560-199604010-00007.